Cancer Science & Therapy

Alberto Bosi

Publications

• Case Report
  Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC)
  Author(s): Vieri Scotti, Virginia Maragna, Fiammetta Meacci, Maria Ausilia Teriaca, Juliana Topulli, Luca Visani, Lorenzo Livi and Alberto BosiVieri Scotti, Virginia Maragna, Fiammetta Meacci, Maria Ausilia Teriaca, Juliana Topulli, Luca Visani, Lorenzo Livi and Alberto Bosi
  
  Nivolumab, a humanized IgG4 programmed death-1 (PD-1) inhibitor antibody, is approved in Italy for advanced non small cell lung cancer (NSCLC), for advanced melanoma in association with ipilimumab, in second line renal cell carcinoma (RCC), in Hodgkin lymphoma relapsed after autologous stem cell transplantation and treatment with brentuximab vedotin, in head and neck squamous cell carcinoma progressed after platinum therapy and in locally advanced urothelial carcinoma unresectable or metastatic after failure of previous platinum therapy. Its immunogenic potential is well known, with described autoimmune-like syndromes, but no clear association is evident for hemolytic anemia. We report case of a 68-year-old man who developed hemolytic anemia after 28 cycles of treatment for advanced Squamous Cell Lung Cancer (SSC)... Read More»
  DOI: 10.4172/1948-5956.1000532

  Abstract PDF